WALTHAM, Mass., July 23, 2018 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its second quarter financial results on Tuesday, August 7, 2018. The Company will host a conference call and live audio webcast at 8:00 a.m.

WALTHAM, Mass., July 16, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS) today announced that the Compensation Committee of the Company's Board of Directors granted Chhaya Shah, in connection with her appointment as the Company's Senior Vice President,

WALTHAM, Mass., July 16, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS) today announced the appointment of Chhaya Shah as Senior Vice President of Technical Operations. "Ms. Shah will help strengthen and expand our technical operations infrastructure,

WALTHAM, Mass., June 07, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that Jesper Høiland, President and Chief Executive Officer and Pepe Carmona, Senior Vice President and Chief Financial Officer of the Company, will present a corporate update at the at the Goldman

Advancing Treatment Care for Osteoporosis

WALTHAM, Mass., May 11, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that Jesper Høiland, President and Chief Executive officer and Pepe Carmona, Senior Vice President and Chief Financial Officer of the Company, will present a corporate update at the Bank of America

First quarter 2018 TYMLOS® sales increase to $14.5 million, a 90% increase  over the fourth quarter of 2017 TYMLOS captured on average 13% of the U.S. anabolic osteoporosis market and 31% of new anabolic patient starts in the quarter Radius targets TYMLOS capturing on average 19-21% of the U.S.

WALTHAM, Mass., April 24, 2018 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its first quarter financial results on Thursday, May 10, 2018. The Company will host a conference call and live audio webcast at 8:00 a.m.

Bridging study will evaluate change in spine bone mineral density (BMD) at 12 months compared with placebo

WALTHAM, Mass., March 22, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today announced that